Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: An international, multicenter, observational study

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Kawamori, Ryuzo ^a   Node, Koichi ^b   Hanafusa, Toshiaki ^c   Atsumi, Yoshihito ^d   Naito, Yusuke ^e   Oka, Yoshitomo ^f  

^a JUNTENDO UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d Life Extension Research Institute   (Japan)

^e Tohoku University Graduate School of Medicine ^*  (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Insulin therapy; Real life clinical data; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; SHORT ACTING INSULIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DIABETES CONTROL; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FOOT ULCER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; JAPANESE; KIDNEY DISEASE; KIDNEY FAILURE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PERIPHERAL NEUROPATHY; POSTPRANDIAL STATE; RETINOPATHY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; WEIGHT GAIN;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TIME-TO-TREATMENT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84883764457     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-131     Document Type: Article

References (26)

1. 5th Edition of the Diabetes Atlas released on World Diabetes Day http://www.idf.org/diabetesatlas/news/fifth-edition-release.
2. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
3. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009, 52:1755-1765.
4. Eliasson B, Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjornsdottir S. Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register. Diabetes Metab 2007, 33:269-276.
5. Kobayashi M, Yamazaki K, Kanatsuka A. Investigation of actual conditions concerning insulin therapy in diabetic patients. Prog Med 2009, 29:1115-1124.
6. Kobayashi M, Yamazaki K, Kanatsuka A, on behalf of the Japanese Diabetes Clinical Data Management Study Group CoDiC(R): Surveillance of clinical management of diabetes in Japan (2 nd report). Jpn J Diabet Mast Clin 2007, 5:401-406. on behalf of the Japanese Diabetes Clinical Data Management Study Group.
7. Rhoads GG, Kosiborod M, Nesto RW, Fonseca VA, Lu SE, Zhang Q, Foody JM. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. Am J Cardiol 2009, 104:910-916.
8. Tong PC, Ko GT, So WY, Chiang SC, Yang X, Kong AP, Ozaki R, Ma RC, Cockram CS, Chow CC, Chan JC. Use of anti-diabetic drugs and glycaemic control in type 2 diabetes-tThe Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2008, 82:346-352.
9. Atsumi Y. Survey on insulin therapy in patients with diabetes -CANDO study, second report-. Shinyaku to Rinsho (J New Rem & Clin) 2010, 59:1447-1465.
10. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008, 371:1753-1760.
11. Freemantle N, Balkau B, Danchin N, Wang E, Marre M, Vespasiani G, Kawamori R, Home PD. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes Obes Metab 2012, 14:901-909.
12. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
13. R Development Core Team R: A Language and Environment for Statistical Computing 2011, Vienna, Austria: R Foundation for Statistical Computing, R Development Core Team.
14. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes A, European Association for Study of D Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care 2009, 32:193-203. American Diabetes A, European Association for Study of D.
15. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care 2012, 35:1364-1379.
16. Japan Diabetes Society Treatment Guide for Diabetes 2012, Tokyo: Bunkodo, Japan Diabetes Society.
17. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S, ORIGIN Trial Investigators Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012, 367:319-328. ORIGIN Trial Investigators.
18. Lonn EM, Bosch J, Diaz R, Lopez-Jaramillo P, Ramachandran A, Hâncu N, Hanefeld M, Krum H, Ryden L, Smith S, McQueen MJ, Dyal L, Yusuf S, Gerstein HC, for the GRACE and ORIGIN Investigators Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE. Diabetes care 2013, Epub ahead of print, for the GRACE and ORIGIN Investigators.
19. Hemmingsen B, Christensen LL, Wetterslev J, Vaag A, Gluud C, Lund SS, Almdal T. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 2012, 344:e1771.
20. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
21. Hu Y, Li L, Xu Y, Yu T, Tong G, Huang H, Bi Y, Weng J, Zhu D. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and beta-cell function in subjects with long-term remission. Diabetes care 2011, 34:1848-1853.
22. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131:182-188.
23. Hayashi T, Kawashima S, Nomura H, Itoh H, Watanabe H, Ohrui T, Yokote K, Sone H, Hattori Y, Yoshizumi M, Ina K, Kubota K, Japan Cholesterol and Diabetes Mellitus Investigation Group Age, gender, insulin and blood glucose control status alter the risk of ischemic heart disease and stroke among elderly diabetic patients. Cardiovasc Diabetol 2011, 10:86. Japan Cholesterol and Diabetes Mellitus Investigation Group.
24. Taskinen MR, Kuusi T, Helve E, Nikkila EA, Yki-Jarvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988, 8:168-177.
25. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317:703-713. UK Prospective Diabetes Study Group.
26. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, D'onofrio F. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993, 44:107-112.